muraglitazar has been researched along with thiophenes in 3 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (thiophenes) | Trials (thiophenes) | Recent Studies (post-2010) (thiophenes) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 17,012 | 1,961 | 8,038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Charbonnel, B | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
| Drosatos, K; Kalliora, C | 1 |
2 review(s) available for muraglitazar and thiophenes
| Article | Year |
|---|---|
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARĪ± and PPARĪ³ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
1 other study(ies) available for muraglitazar and thiophenes
| Article | Year |
|---|---|
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |